大麻对多发性硬化症患者急迫性尿失禁的影响：一项多中心、随机、安慰剂对照试验（CAMS-LUTS）。
The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
作者信息
Freeman R M, Adekanmi O, Waterfield M R, Waterfield A E, Wright D, Zajicek J
机构信息
Urogynaecology Unit, Derriford Hospital, Plymouth, Devon, UK.
出版信息
Int Urogynecol J Pelvic Floor Dysfunct. 2006 Nov;17(6):636-41. doi: 10.1007/s00192-006-0086-x. Epub 2006 Mar 22.
OBJECTIVE
To test whether cannabinoids reduce urge incontinence episodes without affecting voiding in patients with multiple sclerosis. This was part of the multicentre trial of the Cannabinoids in Multiple Sclerosis (CAMS) study.
SUBJECTS AND METHODS
The CAMS study randomised 630 patients to receive oral administration of cannabis extract, Delta(9)-tetrahydrocannabinol (THC) or matched placebo. For this substudy subjects completed incontinence diaries.
RESULTS
All three groups showed a significant reduction, p<0.01, in adjusted episode rate (i.e. correcting for baseline imbalance) from baseline to the end of treatment: cannabis extract, 38%; THC, 33%; and placebo, 18%. Both active treatments showed significant effects over placebo (cannabis extract, p=0.005; THC, p=0.039).
CONCLUSION
The findings are suggestive of a clinical effect of cannabis on incontinence episodes in patients with MS. This is in contrast to the negative finding of the CAMS study, where no difference was seen in the primary outcome of spasticity.
目的
测试大麻素是否能减少多发性硬化症患者的急迫性尿失禁发作次数，同时不影响排尿。这是大麻素治疗多发性硬化症（CAMS）多中心试验的一部分。
受试者与方法
CAMS研究将630名患者随机分组，分别口服大麻提取物、Δ⁹-四氢大麻酚（THC）或匹配的安慰剂。在这项子研究中，受试者完成了尿失禁日记。
结果
从基线到治疗结束，所有三组经调整后的发作率（即校正基线不平衡后）均显著降低，p<0.01：大麻提取物组降低38%；THC组降低33%；安慰剂组降低18%。两种活性治疗组与安慰剂组相比均显示出显著效果（大麻提取物组，p = 0.005；THC组，p = 0.039）。
结论
这些发现提示大麻对多发性硬化症患者的尿失禁发作有临床疗效。这与CAMS研究的阴性结果形成对比，在该研究中，痉挛的主要结局未观察到差异。
Zotero 插件